This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dr. Mark Freedman To Join Opexa’s Scientific Advisory Board

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced it has recently added a key international opinion leader to its Scientific Advisory Board. Mark Freedman, M.D., is a professor of medicine in the field of neurology at the University of Ottawa, and director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, General Campus. He will be joining other colleagues of high regard on Opexa’s Scientific Advisory Board: Dawn McGuire, M.D. (Chair), Doug Arnold, M.D., Edward Fox, M.D., Ph.D., Hans-Peter Hartung, M.D., Clyde Markowitz, M.D., Paul O’Connor, M.D., and Arthur Vandenbark, Ph.D.

“It is a distinct pleasure to welcome Dr. Freedman to Opexa’s Scientific Advisory Board,” stated Dr. McGuire, Chair of the SAB. “Dr. Freedman is internationally renowned for his expertise in MS translational research and has been involved in numerous clinical trials in patients with MS. We will benefit greatly from his clinical and scientific insights as we move to the next phase of Tovaxin development for MS.”

“As a neuroimmunologist, I have carefully followed Opexa’s technology for some time and have always been intrigued about this novel approach to treating MS patients,” commented Dr. Freedman. “As a personalized and targeted therapy with an excellent safety profile, Tovaxin may prove to be a differentiated product for the treatment of both Relapsing Remitting and Secondary Progressive MS patients. I look forward to using my knowledge and experience to guide the Company in their efforts to further develop Tovaxin for patients with MS.”

Mark Freedman, M.D. Bio

Dr. Freedman is currently professor of medicine in the field of neurology at the University of Ottawa, as well as director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, General Campus. He holds his specialist certification in Quebec CSPQ and all of Canada FRCP(C) and is a Fellow of the American Academy of Neurology (FAAN).

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs